In the absence of an optimal method of response assessment, we adopted a pragmatic approach to measure response by clinical, radiological and pathological criteria to evaluate whether ER, PgR, HER-2 status or Ki-67 proliferation index before or after treatment predict response to anthracycline-based PST in women with primary breast cancer. Here, PGR is linked to breast carcinoma.